- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
The deal comes as Abbott works to complete two pending transactions worth nearly $40 billion combined and is the latest in the slew of ophthalmology deals.
U.S. stocks ended Friday's session lower as a crude oil selloff pressures the energy sector and nerves over next week's Federal Reserve meeting peak.
Abbott Laboratories (ABT) will sell its eye surgery unit to Johnson & Johnson (JNJ) for $4.325 billion in cash.